SCHEMBL6459387

SCHEMBL6459387

COc1cc(NC(=S)NC2CCC(Nc3nccc(N(C)C)n3)CC2)cc(OC)c1OC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.42
GAA P10253 2/20 0.42
RAB9A P51151 1/20 0.42
KDM4E B2RXH2 2/20 0.42
KIT P10721 1/20 0.41
PDGFRA P16234 1/20 0.41
IGF1R P08069 3/20 0.41
ACHE P22303 1/20 0.41
BACE1 P56817 1/20 0.41
CNR1 P21554 1/20 0.39
KCNH2 Q12809 1/20 0.39
AURKB Q96GD4 1/20 0.39
PTK2 Q05397 1/20 0.39
MCHR1 Q99705 1/20 0.39
HTT P42858 1/20 0.39
KMT2A Q03164 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
MAPK8 P45983 1/20 0.37
MAPK9 P45984 1/20 0.37
MAPK10 P53779 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6459383 1.00 ALDH1A1 (0.42) ALDH1A1GAARAB9AKDM4EKIT
SCHEMBL6457399 0.90 KIT (0.45) ALDH1A1GAARAB9AKDM4EKIT
SCHEMBL6457387 0.90 KIT (0.45) ALDH1A1GAARAB9AKDM4EKIT
SCHEMBL6456655 0.89 AURKB (0.44) ALDH1A1KDM4EKITPDGFRAIGF1R
SCHEMBL6456663 0.89 AURKB (0.44) ALDH1A1KDM4EKITPDGFRAIGF1R
SCHEMBL6463067 0.84 ALDH1A1 (0.48) ALDH1A1GAARAB9AKDM4ECNR1
SCHEMBL6463074 0.84 ALDH1A1 (0.48) ALDH1A1GAARAB9AKDM4ECNR1
SCHEMBL6878402 0.83 LMNA (0.56) ALDH1A1HTTSMN1; SMN2MAPK8MAPK9
SCHEMBL6878392 0.83 LMNA (0.56) ALDH1A1HTTSMN1; SMN2MAPK8MAPK9
SCHEMBL6460836 0.83 ALDH1A1 (0.57) ALDH1A1PDGFRAMCHR1HTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof TAISHO PHARMACEUTICAL CO., LTD. 2005-09-08 US claimed
WO-2004087669-A1 NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF TAISHO PHARMACEUTICAL CO. LTD. (JP) 2004-10-14 WO claimed
EP-1464335-A2 Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist Taisho Pharmaceutical Co. Ltd. (JP) 2004-10-06 EP claimed
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof TAISHO PHARMACEUTICAL CO., LTD. 2005-09-08 US disclosed
WO-2004087669-A1 NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF TAISHO PHARMACEUTICAL CO. LTD. (JP) 2004-10-14 WO disclosed
EP-1464335-A2 Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist Taisho Pharmaceutical Co. Ltd. (JP) 2004-10-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof HCRTR2, MCHR1, MCHR2 ALDH1A1 2036/4885GAA 484/4885RAB9A 1648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.